专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

GB201103311D0 Mobile theft security 未知
公开(公告)号：GB201103311D0
公开(公告)日：2011-04-13
申请号：GB201103311
申请日：2011-02-28
申请人： TURNER SEAN C

2. 发明申请

WO2010135560A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF 审中-公开
标题翻译： 5-HT受体的调节剂及其使用方法
公开(公告)号：WO2010135560A1
公开(公告)日：2010-11-25
申请号：PCT/US2010/035626
申请日：2010-05-20
申请人： ABBOTT LABORATORIES , AKRITOPOULOU-ZANZE, Irini , BRAJE, Wilfried , DJURIC, Stevan, W. , WILSON, Noel, S. , TURNER, Sean, C. , KRUGER, Albert, W. , RELO, Ana-Lucia , SHEKHAR, Shashank , WELCH, Dennie, S. , ZHAO, Hongyu , GANDARILLA, Jorge , GASIECKI, Alan, F. , LI, Huanqiu , THOMPSON, Christina, M. , ZHANG, Min
发明人： AKRITOPOULOU-ZANZE, Irini , BRAJE, Wilfried , DJURIC, Stevan, W. , WILSON, Noel, S. , TURNER, Sean, C. , KRUGER, Albert, W. , RELO, Ana-Lucia , SHEKHAR, Shashank , WELCH, Dennie, S. , ZHAO, Hongyu , GANDARILLA, Jorge , GASIECKI, Alan, F. , LI, Huanqiu , THOMPSON, Christina, M. , ZHANG, Min
IPC分类号： C07D487/04 , C07D491/04 , C07D495/04 , A61P25/00 , A61K31/551 , A61K31/554 , A61K31/553
CPC分类号： C07D513/04 , C07D487/04 , C07D491/04 , C07D491/044 , C07D495/04 , C07D495/16
摘要： The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[ c ]pyrrole, and octahydrocyclohepta[ c ]pyrrole derivatives of formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , A, Y 1 , Y 2 , and Y 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
摘要翻译：本申请涉及式（I）的芳基 - 和杂芳基 - 稠合十氢吡咯并氮平，八氢恶庚英吡咯，八氢吡咯并噻吩二恶烷，十氢环庚三烯并[c]吡咯和八氢环庚三烯并[c]吡咯衍生物，其中R1，R2，R3，R4，R5， Y1，Y2和Y3如说明书中所定义。本申请还涉及包含这些化合物的组合物，制备此类化合物的方法，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

3. 发明申请

WO2006063178A3 THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF 审中-公开
标题翻译：抑制香草酸受体亚型1（VR1）的噻吩基化合物及其应用
公开(公告)号：WO2006063178A3
公开(公告)日：2006-08-24
申请号：PCT/US2005044500
申请日：2005-12-07
申请人： ABBOTT LAB , TURNER SEAN C , JINKERSON TAMMIE K , GOMTSYAN ARTHUR R , LEE CHIH-HUNG
发明人： TURNER SEAN C , JINKERSON TAMMIE K , GOMTSYAN ARTHUR R , LEE CHIH-HUNG
IPC分类号： C07D495/04 , A61K31/4365 , A61P13/10 , A61P29/00
CPC分类号： C07D495/04 , C07D498/04
摘要： The present invention discloses fused thienopyridyl compounds of general formula (I), wherein X 1 -X 6 , R 5 -R 7 , Z 1 and L are as defined in the description. The resent invention also discloses a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain, urinary incontinence, bladder overactivity, and inflammatory thermal hyperalgesia in mammals, and pharmaceutical compositions including those compounds.
摘要翻译：本发明公开了通式（I）的稠合噻吩并吡啶基化合物，其中X 1〜X 6，R 5，-R 7，，Z _{1 和L如说明书中所定义。本发明还公开了使用这些化合物抑制哺乳动物中的VR1受体的方法，用于控制哺乳动物的疼痛，尿失禁，膀胱过度活动和炎性热痛觉过敏的方法，以及包含这些化合物的药物组合物。}

4. 发明申请

WO2006040182A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的异种化合物
公开(公告)号：WO2006040182A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011106
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe , BACKFISCH, Gisela , BEYERBACH, Armin , LUBISCH, Wilfried
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe , BACKFISCH, Gisela , BEYERBACH, Armin , LUBISCH, Wilfried
IPC分类号： C07D207/09 , C07D401/12 , C07D405/12 , C07D409/12 , C07D401/04 , C07D403/04 , C07D413/12 , C07D205/04 , C07D413/10 , C07D413/14 , C07D211/28 , A61K31/397 , A61K31/445 , A61P25/16
CPC分类号： C07D413/14 , C07D205/04 , C07D207/09 , C07D211/28 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12
摘要： The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C,-C 6 -alkyl, C,-C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C l -C 6 -hydroxyalkyl, fluorinated C,-C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中n为0,1或2; G是CH

5. 发明申请

WO2006040179A1 AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的氨基甲醛化合物
公开(公告)号：WO2006040179A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011092
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
IPC分类号： C07C311/29 , C07C311/21 , C07D213/76 , C07D207/09 , C07C317/22 , C07C317/14 , A61K31/18 , A61K31/44 , A61P25/18
CPC分类号： C07D213/76 , C07C311/21 , C07C311/29 , C07C2601/02 , C07D207/09
摘要： The present invention relates to aromatic compounds of the formula (I) wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry 1 or 2 radicals R b ; X is N or CH; E is CR 6 R 7 or NR 3 ; R 1 is C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C l -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, or R 1a and R 2 together are (CH 2 ) n with n being 2, 3 or 4, or R 1a and R 2a together are (CH 2 ) n with n being 2, 3 or 4; R 2 and R 2a are independently of each other H, C 1 -C 4 -alkyl or fluorinated C 1 -C 4 -alkyl or R 2a and R 2 together are (CH 2 ) m with m being 1, 2, 3, 4 or 5; R 3 is H or C 1 -C 4 -alkyl; R 6 , R 7 independently of each other are selected from H, fluorine, C 1 -C 4 -alkyl and fluorinated C 1 -C 4 -alkyl or together form a moiety (CH 2 ) p with p being 2, 3, 4 or 5; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D 3 receptor ligand.
摘要翻译：本发明涉及式（I）的芳族化合物，其中Ar是苯基或芳族5-或6-元C-结合杂芳族基团，其中Ar可以携带1个基团R 1

6. 发明申请

WO2006040176A1 AZABICYCLOHEPTYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节紊乱的化学物质
公开(公告)号：WO2006040176A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011089
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
IPC分类号： C07D209/52 , C07D403/12 , C07D405/12 , C07D409/12 , A61K31/00 , A61P25/28
CPC分类号： C07D401/12 , C07D209/52 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention relates to a compound of the formula (I) wherein R 1 is H, C 1 -C 6 -alkyl which may be substituted by C 3 -C 6 -cycloalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a ; wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中R

7. 发明申请

WO2005007642A3 NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN 审中-公开
标题翻译：新的AZAHETEROCYCLIC辅助剂用于治疗疼痛
公开(公告)号：WO2005007642A3
公开(公告)日：2005-05-26
申请号：PCT/US2004021836
申请日：2004-07-09
申请人： ABBOTT LAB , ZHENG GUO ZHU , BROWN BRIAN S , TURNER SEAN C , WHITE TAMMIE K , SCHMIDT ROBERT G , KOENIG JOHN R , LEE CHIH-HUNG
发明人： ZHENG GUO ZHU , BROWN BRIAN S , TURNER SEAN C , WHITE TAMMIE K , SCHMIDT ROBERT G , KOENIG JOHN R , LEE CHIH-HUNG
IPC分类号： A61P25/04 , C07D401/04 , C07D487/08 , A61K31/4525 , A61K31/4995 , C07D401/12
CPC分类号： C07D401/04 , C07D487/08
摘要： The present invention relates to compounds of formula (I-VII) (I), or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7and R8 are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.
摘要翻译：本发明涉及式（I-VII）（I）化合物或其药学上可接受的盐或前药，其中A，L，R6，R7和R8如本文所定义。本发明还涉及使用这些化合物和包括这些化合物的药物组合物来治疗疼痛的方法。

8. 发明申请

WO2006058753A1 TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULAIONT OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节症状的三唑化合物
公开(公告)号：WO2006058753A1
公开(公告)日：2006-06-08
申请号：PCT/EP2005/012856
申请日：2005-12-01
申请人： ABBOTT GMBH & CO. KG , UNGER, Liliane , HAUPT, Andreas , BEYERBACH, Armin , DRESCHER, Karla , BRAJE, Wilfried , DARBYSHIRE, John , TURNER, Sean, C. , BACKFISCH, Gisela
发明人： UNGER, Liliane , HAUPT, Andreas , BEYERBACH, Armin , DRESCHER, Karla , BRAJE, Wilfried , DARBYSHIRE, John , TURNER, Sean, C. , BACKFISCH, Gisela
IPC分类号： A61K31/506 , C07D403/12 , A61P25/18
CPC分类号： C07D403/12
摘要： The invention relates to compounds of formula (I), wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R 1 on the remaining carbon atom and a radical R 1a on one of the nitrogen atoms; R 1 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxymethyl, fluorinated C 1 -C 6 alkyl, fluorinated C 3 -C 6 cycloalkyl, fluorinated C 1 -C 4 alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl; R 1a is hydrogen or C 1 -C 4 alkyl; and R 2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, fluorinated C 1 -C 6 alkyl or fluorinated C 3 -C 6 cycloalkyl; and to the physiologically tolerated acid addition salts of there compounds. The invention also relates to a pharmaceuticaly composition that comprises at least one triazole compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one traizole compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.
摘要翻译：本发明涉及式（I）化合物，其中n是1或2，Ar是在剩余的碳原子上带有自由基R 1的C结合的1,2,4-三唑基和其中一个氮原子上的基团R 1a; R 1是氢，C 1 -C 6烷基，C 3 -C 6烷基，C 1 -C 6烷基，C 1 -C 6烷基，氟化C 1 -C 6烷基，氟化C 1 -C 6烷基，C 1 -C 6烷基，C 1 -C 6烷基，氟化C 1 -C 4烷氧基甲基或任选取代的苯基或5-或6位的C 1 -C 6烷基，杂芳基; R 1a是氢或C 1 -C 4烷基; R 2是C 1 -C 6烷基，C 3 -C 6烷基，C 3 -C 6烷基，C 3 -C 6烷基，C 3 -C 6烷基，氟化C 1 -C 6烷基或氟化C 3 -C 6环烷基; 以及该化合物的生理耐受酸加成盐。本发明还涉及包含至少一种式（I）的三唑化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及治疗有益于多巴胺D 3受体拮抗剂或多巴胺D 3激动剂，所述方法包括给受试者施用有效量的式（I）化合物或生理学耐受的酸加成盐，需要。

9. 发明申请

WO2006040178A1 ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译： ARYLSULFONYLMETHYL或ARYLSULFANAMID替代芳香化合物适用于治疗多巴胺D3受体制剂的病症
公开(公告)号：WO2006040178A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011091
申请日：2005-10-14
申请人： ABBOTT GMBH & CO.KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe
IPC分类号： C07D311/04 , C07D215/38 , C07C211/19 , A61K31/13 , A61K31/47 , A61K31/35 , A61P25/16
CPC分类号： C07C311/21 , C07C311/29 , C07C311/44 , C07C2601/02 , C07C2602/10 , C07D207/10 , C07D211/10 , C07D215/38 , C07D239/84 , C07D263/32 , C07D277/82 , C07D311/04 , C07D413/04 , C07D491/04
摘要： The present invention relates to aromatic compounds of the formula (I), wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry 1 or 2 radicals R b ; X is N or CH; Y is O, S, -CH=N-, -CH=CH- or -N=CH-; A is CH 2i O or S; E is CR 6 R 7 or NR 3 ; R 1 is C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C4-cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C,-C 3 -alkylcarbonyl; R 1a is H, C 2 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, or R 1a and R 2 together are (CH 2 ) n with n being 2 or 3, or R 1 a and R 2a together are (CH 2 ) n with n being 2 or 3; R 2 and R 2a are independently of each other H, CH 3 , CH 2 F, CHF 2 or CF 3 ; R 3 is H or C 1 -C 4 -alkyl; R 6 , R 7 independently of each other are selected from H, C 1 -C 2 -alkyl and fluorinated C 1 -C 2 -alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）的芳族化合物，其中Ar是苯基或芳族5-或6-元C-结合的杂芳族基团，其中Ar可以携带1个基团R 1

10. 发明申请

WO2005016890A1 FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR 审中-公开
标题翻译：抑制VANILLOID受体亚型1（VR1）受体的融合的偶氮化合物
公开(公告)号：WO2005016890A1
公开(公告)日：2005-02-24
申请号：PCT/US2004/025109
申请日：2004-08-04
申请人： ABBOTT LABORATORIES , LEE, Chih-Hung , BAYBURT, Erol, K. , DIDOMENICO, Stanley, Jr. , DRIZIN, Irene , GOMTSYAN, Arthur, R. , KOENIG, John, R. , PENNER, Richard, J. , SCHMIDT, Robert, G., Jr. , TURNER, Sean, C. , WHITE, Tammie, K. , ZHENG, Guo Zhu
发明人： BAYBURT, Erol, K. , DIDOMENICO, Stanley, Jr. , DRIZIN, Irene , GOMTSYAN, Arthur, R. , KOENIG, John, R. , PENNER, Richard, J. , SCHMIDT, Robert, G., Jr. , TURNER, Sean, C. , WHITE, Tammie, K. , ZHENG, Guo Zhu
IPC分类号： C07D217/24
CPC分类号： C07D249/08 , C07D209/08 , C07D217/02 , C07D217/22 , C07D217/24 , C07D217/26 , C07D231/12 , C07D231/56 , C07D233/56 , C07D237/28 , C07D401/12 , C07D405/12
摘要： Compounds of Formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
摘要翻译：式（I）化合物是可用于治疗疼痛，炎症性热痛觉过敏，尿失禁和膀胱过度活动的新型VR1拮抗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式